<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711032</url>
  </required_header>
  <id_info>
    <org_study_id>3475-676</org_study_id>
    <secondary_id>MK-3475-676</secondary_id>
    <secondary_id>2018-001967-22</secondary_id>
    <secondary_id>194713</secondary_id>
    <nct_id>NCT03711032</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)</brief_title>
  <official_title>A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the antitumor efficacy and safety of pembrolizumab in
      combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is
      persistent or recurrent following adequate BCG induction. The primary hypothesis is that the
      combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed
      by central pathology review compared to BCG in participants with carcinoma in situ (CIS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">November 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CRR) by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to ~3.5 years</time_frame>
    <description>CRR is defined as the percentage of participants with CIS achieving a complete response (CR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>EFS is defined as the time from randomization until the recurrence or progression of HR NMIBC, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-Free Survival (RFS)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>RFS is defined as the time from randomization until the first occurrence of any urothelial carcinoma (UC) recurrence, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival (DSS)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>DSS is defined as the time from randomization to death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cystectomy</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>Time to cystectomy is defined as the time from a participant's randomization until the date of cystectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month EFS Rate</measure>
    <time_frame>12 months after EFS (up to ~5 years)</time_frame>
    <description>The 12-month EFS rate is defined as the percentage of participants with EFS at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>DOR is defined as the time from first documented CR until end of response or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month DOR Rate</measure>
    <time_frame>12 months after CR (up to ~4.5 years)</time_frame>
    <description>The 12-month DOR Rate is defined as the percentage of participants with a CR of at least 12 months duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Drug Due to AEs</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. The change from baseline in Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-Non-muscle Invasive Bladder Cancer Module 24 (NMIBC24) Total Score</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EORTC-QLQ-NMIBC24 is a 24-item questionnaire developed to supplement the EORTC QLQ-C30 in high-risk NMIBC patients. Each item is scored out of 4 total points (1=Not at All to 4=Very Much). All responses are transformed from 0 to 100, with a high score indicating more symptoms or problems. The change from baseline in EORTC-QLQ-NMIBC24 total score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS)</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. The change from baseline in EQ-5D-5L VAS will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the EORTC-QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score</measure>
    <time_frame>Time of last PRO assessment (up to ~2 years)</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. TTD in Global Health Status/Quality of Life is defined as the time from baseline to the first onset of a 10 point or greater decrease from baseline in the Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score, with or without subsequent confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS)</measure>
    <time_frame>Time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. TTD in EQ-5D-5L VAS is defined as the time from baseline to the first onset of a 7 point or greater decrease from baseline in EQ-5D-5L VAS, with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>High-risk Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG plus Pembrolizumab (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG (Induction and Maintenance), in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG (Arm 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG monotherapy (Induction and Maintenance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab IV infusion of 200 mg Q3W</description>
    <arm_group_label>BCG plus Pembrolizumab (Arm 1)</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy</description>
    <arm_group_label>BCG (Arm 2)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab (Arm 1)</arm_group_label>
    <other_name>TICE® BCG</other_name>
    <other_name>OncoTICE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically-confirmed diagnosis of non-muscle invasive (T1, high grade Ta
             and/or CIS) transitional cell carcinoma (TCC) of the bladder

          -  Has been treated with one adequate course of BCG induction therapy for the treatment
             of HR NMIBC

          -  Following adequate BCG induction therapy, must have persistent or recurrent HR NMIBC

          -  Has undergone cystoscopy/ transurethral resection of bladder tumor (TURBT) to remove
             all resectable disease

          -  Has provided tissue for biomarker analysis

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Has adequate organ function

          -  Male participants must agree to use approved contraception during the treatment period
             and for at least 120 days after the last dose of study treatment and refrain from
             donating sperm during this period

          -  Female participants who are not pregnant, not breastfeeding, and either not a woman of
             child bearing potential (WOCBP) or are a WOCBP who agrees to use approved
             contraception during the treatment period and for at least 120 days after the last
             dose of study treatment

        Exclusion Criteria:

          -  Has persistent T1 disease following an induction course of BCG

          -  Has a history of or concurrent muscle invasive (i.e., T2, T3, T4), locally advanced
             non-resectable or metastatic UC

          -  Has concurrent extra-vesical (i.e., urethra, ureter, renal pelvis) non-muscle invasive
             TCC of the urothelium, concurrent upper tract involvement, or invasive prostatic TCC
             including T1 or greater disease, or ductal invasion

          -  WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization

          -  Has received prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an
             agent directed to another co-inhibitory T-cell receptor

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 4 weeks of start of study treatment

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks of start of study treatment

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days of start of study
             treatment

          -  Has a known additional malignancy that is progressing or requires active treatment
             within the past 3 years

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis

          -  Has one or more of the following contraindications to BCG: prior BCG sepsis or
             systemic infection, total bladder incontinence, or an adverse experience to a previous
             BCG instillation that resulted in treatment discontinuation and precludes retreating
             with BCG

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection

          -  Has current active tuberculosis

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment

          -  Has had an allogenic-tissue/solid organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083)</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>907-276-1455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA ( Site 1052)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-3421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center ( Site 1061)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-456-8148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skyline Urology ( Site 1065)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-602-5005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center ( Site 1056)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-243-2177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists, PA ( Site 8002)</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Urology ( Site 1092)</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>678-344-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University ( Site 1076)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-4823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wichita Urology Group ( Site 1086)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-636-6141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 1062)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-8862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology ( Site 1077)</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-786-0467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Urology Associates ( Site 1055)</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center ( Site 1090)</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-971-5373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey ( Site 1059)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-235-6048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital Cancer Care Center ( Site 1087)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>518-438-1019</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health- Monter Cancer Center ( Site 1080)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-734-8500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY ( Site 1078)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>31547841857794</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-State Urologic Services PSC, Inc. ( Site 1091)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-841-7555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center ( Site 1066)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-844-6031</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Arthur G James Cancer Hospital &amp; Richard J Solove Research Institute ( Site 10</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-7421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute ( Site 1075)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>971-262-9600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidLantic Urology ( Site 1071)</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>610-667-0458</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lancaster Urology ( Site 1079)</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>717-431-2285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 1088)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-662-2891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center ( Site 1085)</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8434491010257</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Associates [Nashville, TN] ( Site 1072)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-250-9268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth Cancer Center ( Site 8003)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Plano West ( Site 8001)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center ( Site 1057)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>802-656-9926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia ( Site 1070)</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>757-452-3463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nothern Cancer Institute ( Site 0003)</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital ( Site 0001)</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen ( Site 0052)</name>
      <address>
        <city>Linz</city>
        <state>Oberosterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4373276777727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik f. Urologie Innsbruck ( Site 0051)</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+435050424811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna ( Site 0054)</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4367761942300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Salzburg ( Site 0053)</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+435725527400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site de Godinne ( Site 0103)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281423858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis Aalst ( Site 0106)</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3253724378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0102)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3292469522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent ( Site 0101)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Exdeo Clinical Research Inc. ( Site 0165)</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2T 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6048515667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silverado Resarch Inc. ( Site 0155)</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2505929988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network ( Site 0160)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068574780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0153)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169462246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0164)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185411000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0157)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51425234005853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS - Hopital Fleurimont ( Site 0152)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819346111012852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Hotel-Dieu de Quebec ( Site 0151)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418525444420414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital [Tampere Finland] ( Site 0201)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331164621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498941402522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden ( Site 0259)</name>
      <address>
        <city>Weiden In Der Oberpfalz</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49963033302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg ( Site 0265)</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4993120132037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brueder Trier ( Site 0262)</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496512082680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena ( Site 0252)</name>
      <address>
        <city>Jena</city>
        <state>Thuringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+491711421827</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Patras ( Site 0302)</name>
      <address>
        <city>Patra</city>
        <state>Peloponnisos</state>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302610999791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa ( Site 0301)</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302413502811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antikarkiniko Nosokomeio Thessalonikis THEAGENIO ( Site 0303)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>540 07</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302310898721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0353)</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osp Generale Reg di Bolzano ( Site 0355)</name>
      <address>
        <city>Bolzano</city>
        <state>Trentino-Sudtirol</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393477835206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II ( Site 0357)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390805555420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi ( Site 0360)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390552758011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino ( Site 0351)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Buccheri La Ferla Fatebenefratelli ( Site 0352)</name>
      <address>
        <city>Palermo</city>
        <zip>90123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39091479432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli ( Site 0358)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Verona - Ospedale Civile Maggiore Borgo Trento ( Site 0356)</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390458123876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital ( Site 0407)</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81172335111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 0414)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899645111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital ( Site 0412)</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81298533900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital ( Site 0403)</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81427788111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokosuka Kyosai Hospital ( Site 0406)</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81468222710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 0411)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81744223051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 0401)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital ( Site 0410)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81922913434</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 0413)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 0404)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666452121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical And Dental University ( Site 0409)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338136111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital ( Site 0405)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81333531211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 0801)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821099288097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0802)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0804)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0803)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 1180)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379492120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre ( Site 0453)</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31433876543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC ( Site 0451)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107041505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital ( Site 0553)</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4793200749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger universitetssykehus ( Site 0555)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4798444505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Guillermo Almenara Irigoyen ( Site 0601)</name>
      <address>
        <city>La Victoria</city>
        <state>Lima</state>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51999437977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncosalud ( Site 0603)</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51992756559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central [Lima, Peru] ( Site 0604)</name>
      <address>
        <city>Lima</city>
        <zip>15076</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51997468543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwesytecki Szpital Kliniczny we Wroclawiu ( Site 0669)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601143281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne ( Site 0679)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48563004380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow ( Site 0668)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601767695</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologica Praktyka Lekarska Adam Marcheluk ( Site 0654)</name>
      <address>
        <city>Siedlce</city>
        <state>Mazowieckie</state>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48504283093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magodent Szpital Elblaska ( Site 0653)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0671)</name>
      <address>
        <city>Koscierzyna</city>
        <state>Pomorskie</state>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48607460282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku ( Site 0655)</name>
      <address>
        <city>Slupsk</city>
        <state>Pomorskie</state>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48598460340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LIFTMED ( Site 0652)</name>
      <address>
        <city>Rybnik</city>
        <state>Slaskie</state>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Sp. z o.o. ( Site 0674)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48616632513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2CA Braga. Centro Clinico Academico ( Site 0705)</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351253027249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Coimbra Francisco Gentil EPE ( Site 0704)</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351239400200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHLN Hospital Santa Maria ( Site 0702)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217805056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Descobertas ( Site 0706)</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351210025200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0701)</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti ( Site 0852)</name>
      <address>
        <city>Lugo</city>
        <state>Lugo [Lugo]</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34982296459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 0862)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 0863)</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia ( Site 0855)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961244188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon ( Site 0854)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Navarra - Madrid ( Site 0860)</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid ( Site 0859)</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917878600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 0857)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0866)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 912 071 876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 1201)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41615565477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG ( Site 1204)</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41795532381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zurich ( Site 1203)</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442555440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Universitesi Hastanesi ( Site 0953)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327149696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi ( Site 0959)</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055250505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0961)</name>
      <address>
        <city>Konya</city>
        <zip>42000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322679838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital ( Site 1006)</name>
      <address>
        <city>Inverness</city>
        <state>Highland</state>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4401463706356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew s Hospital ( Site 1008)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078828505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Georges University Hospitals NHS Foundation Trust. ( Site 1005)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442087253362</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death receptor 1 (PD-1)</keyword>
  <keyword>programmed cell death ligand 1 (PD-L1)</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>anti-PD-L1</keyword>
  <keyword>BCG</keyword>
  <keyword>HR NMIBC</keyword>
  <keyword>Patient Reported Outcome (PRO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

